Digistain is a clinical diagnostics company that aims to eliminate breast cancer care inequalities by transforming the speed, cost and accuracy of risk recurrence prediction. The company has developed a new MHRA-cleared technology for guiding adjuvant therapy in Early Breast Cancer. Digistain works biologically downstream using a proprietary method to measure markers at a protein level to deliver a personalised risk of recurrence score in Early Breast Cancer. The technology is based on 15 years of research and development pioneered by respected cancer scientists from the NHS, Cancer Research UK and Imperial College together with input from over 1500 oncologists.
Oncologists and General Practitioners with special interest in Oncology.
This product package all the necessary professional information for Digistain including:
For more information visit digistain.co.uk.